Since legalization, the cannabis boom has completely changed the investment landscape in North America. Investors have rushed to grab the opportunity and venture capital invested over $1 billion in cannabis stocks in 2018. This rush of capital, mostly focused on producers, has led to a glut in supply and disappointing results for major cannabis companies like Aurora Cannabis Inc. (NYSE: ACB) and Canopy Growth Corporation (NYSE: CGC).
This raises a dilemma for cannabis investors. While the sector will undoubtedly continue to grow, producers represent a big risk. The legal landscape also remains confusing and there is no guarantee that major markets like Europe will open their doors to cannabis any time soon.
The solution? Invest in a company that takes advantage of multiple sectors. Rapid Dose Therapeutics Inc. (CSE: DOSE, OTC: RDTCF) has positioned itself to take advantage of rapid growth in the cannabis sector whilst also targeting other lucrative sectors including the nutraceutical and pharma markets with its QuickStrip™ technology.
RDT’s QuickStrip™ technology a disruptor in its own right
Rapid Dose Therapeutics Inc. (CSE: DOSE, OTC: RDTCF) CEO, Mark Upsdell’s Canadian life sciences company provides disruptive proprietary drug delivery technologies designed to improve patient outcomes. RDT takes drug delivery to a new level and provides Quick, Convenient, Precise, and Discreet™ dosing.
Within the cannabis sector, RDT operates as a service provider for the cannabis industry. RDT owns its proprietary manufacturing equipment and licences their delivery technology. Their service-based annuity contracts help to drive recurring revenue and enable rapid expansion into emerging markets.
Timing is everything, and RDT is creating a lucrative opportunity for licensed producers and growers in the cannabis sector to provide a Smoke-Free Choice™ to cannabis consumers.
What we’ve seen in the cannabis space is very similar to what happened when Prohibition ended, which is very instructive. So, I think from a company perspective we’re well-positioned to take advantage of future growth in this cycle.Mark Upsdell, CEO, Rapid Dose Therapeutics Inc.
QuickStrip™ — how it works
RDT has developed a non-inhalation proprietary delivery system called QuickStrip™. This is an oral film strip designed to dissolve under the tongue (sublingually) or inside the cheek (buccally). Oral film strips can deliver not only cannabis products, but also nutraceuticals, pharmaceuticals, and other therapeutic products. This makes it an attractive opportunity for potential investors who can potentially benefit from multiple high-growth markets simultaneously.
The QuickStrip™ technology enables the delivery of the active ingredient quickly and precisely into the bloodstream while bypassing the gastrointestinal tract (first-pass metabolism). This delivery method can significantly boost bioavailability and promote the rapid onset of the active ingredient — providing consumers quick results.
“The oral mucosa inside the mouth, contains tissue that enables the passing of products into the bloodstream,” says RDT’s SVP of Business Development, Jason Lewis.
“A challenge in healthcare, has been to find a solution which delivers therapeutics across those membranes effectively with ease for the consumer. We believe QuickStrip™ is that consumer-focused solution.”
A collaborative bioanalytical study between RDT and University of Nevada, Las Vegas (UNLV) was published in the high impact journal, Frontiers in Pharmacology. The study was conducted in collaboration with researchers from UNLV to evaluate QuickStrip™ oral film delivery, in mice, of caffeine for onset time, bioavailability, and effects on the central nervous system, compared to direct administration into the stomach.
“Our work demonstrated that by using this technology, caffeine was delivered into the bloodstream quickly and with up to twice the bioavailability of traditional means,” said Dustin Hines, UNLV neuroscientist and study co-author.
The applications for QuickStrip™ technology are almost unlimited
There is significant potential to expand the company’s three product verticals. For example, the QuickStrip™ nutraceutical product line rapidly delivers B12, melatonin, and caffeine. Future pharmaceutical applications could transform how medication is taken from the young to the elderly. Within the cannabis sector, QuickStrip™ provides a precise, smoke-free delivery alternative for cannabis, a solution preferred by many consumers.
He also notes that while cannabis might be the focus of attention right now, future product development and QuickStrip™ delivery of other active ingredients may revolutionize how therapeutics are delivered overall. This could be a big bonus for consumers and also for investors in the Company.
“If you think of a patient who has dysphagia, trouble swallowing, they have few alternatives such as patches or invasive injections. It is time to deliver medication in a new and effective way, with a focus on improving both patient and consumer outcomes.” says Lewis.
RDT public on CSE:DOSE
RDT was publicly listed December 17, 2018 on the CSE and has been making rapid inroads since. Rapid Dose Therapeutics received its cannabis micro-processing licence by Health Canada in November 15, 2019. This licence will enable RDT to manufacture their QuickStrip™ cannabis products to the Canadian markets, in addition to their existing contracts within the U.S. and European markets.
RDT was then successfully awarded a NSERC Collaborative Research and Development (CRD) grant with McMaster University. The research will receive a total funding amount of $540,000 over three years, effective January 1, 2020.
Furthermore, in January 2020, RDT has secured government funding of $400,000 from The National Research Council of Canada Industrial Research Assistance (NRC-IRAP), to support a project focused on commercial development and scale-up manufacturing of cannabis infused QuickStrip™ products.
“This grant funding award from NRC-IRAP will help support speed to market for RDT’s QuickStrip™ and enables scale-out production to supply global markets, demonstrate superior product performance for customers while strengthening the Company’s IP portfolio,” said Mark Upsdell, CEO and Founder of RDT.
Mark then added “We have an opportunity to do many things from an R&D and product development perspective. We will continue to expand into the health and wellness marketplace as we move forward. We have the right ingredients to propel RDT — the facility to expand, a strong executive team and strategic relationships to expand the Corporation and revolutionize therapeutic delivery in emerging markets.”
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
Sono Motors introduces community advisory board
Sono Motors unveiled the latest prototype of its electric minivan with solar cells in the body. In parallel with the...
Ysios Capital invests 30 million in 2020 and plans to enter four companies in 2021
In a year marked by the COVID-19 pandemic, the venture capital manager Ysios Capital carried out six follow-on operations and...
Oxxo enters the fintech ecosystem with its digital wallet Spin
On March 2nd, Oxxo presented Spin, a digital wallet through which it will be possible to manage, send and receive...
AEDESEO asks for €57,000 in crowdfunding to research a new treatment
AEDESO wants to start a clinical study and launched a crowdfunding campaign to raise the necessary money for it. Patients...
Mainz-based biotech company ActiTrexx receives €3.5 million in financing
The biotech company ActiTrexx has recently closed a Series A financing round, during which it raised $4.2 million (€3.5 million)....
Biotech6 days ago
VB Devices closes a €1.1 million round to consolidate its market entry
Business6 days ago
The multifaceted benefits of Augmented and Virtual Reality in education
Featured6 days ago
ARisk, the startup of predictive risk algorithms, closes €350,000 round
Cannabis5 days ago
Legalization trend drives cannabis ETFs to significantly grow